Quick Summary
| Detail | |
|---|---|
| Compounds involved | BPC-157 and TB-500 (Thymosin Beta-4 fragment) |
| Nickname origin | Community reference to the X-Men character Wolverine's fictional rapid-healing ability |
| What it's used for | Discussed in the peptide community for tissue repair, wound healing, and recovery |
| Evidence status | Preclinical/animal research on each compound separately; no combined-arm human trial of the pairing |
Where the "Wolverine Stack" Name Comes From
"Wolverine stack" isn't a scientific or medical term. It's an informal nickname that emerged inside the peptide research community for combining BPC-157 and TB-500, two peptides both associated with tissue-repair research. The name is a reference to the X-Men character Wolverine, whose signature mutant ability is a fictional "healing factor" that lets him recover from injury at an accelerated, almost instant rate. Because both compounds have a reputation in the community for supporting tissue repair, the pairing picked up the nickname as shorthand, not because any clinical study has shown human recovery on the level of a comic book character.
It's worth being direct about that distinction up front: the name is catchy and it captures the intent behind the stack, but it says nothing about how strong the actual evidence is. That's covered further down this page.
What's Actually In It
BPC-157 is a synthetic peptide based on a fragment of a protein naturally found in human gastric juice. It has been studied in animal models for gut healing, tendon and ligament repair, and anti-inflammatory effects, and it's one of the most discussed compounds in the peptide research space.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in cell migration, wound healing, and angiogenesis (the formation of new blood vessels). Like BPC-157, it has been studied primarily in animal models rather than in large human trials.
Why These Two Are Combined
The rationale behind pairing BPC-157 and TB-500 comes down to the different angles each compound is studied from. BPC-157 has been researched broadly across many tissue types, including gut healing, tendon and ligament repair, and inflammation. TB-500 has been researched more specifically around cell migration and wound or tissue repair through a different mechanism, involving actin regulation and angiogenesis. Combining them is thought to approach tissue repair from two separate directions rather than relying on a single mechanism.
Mechanistic extrapolation, not a tested combination: that rationale is built by reasoning across separate research on each compound individually. No dedicated study has tested the BPC-157 and TB-500 combination itself as a combined arm, so the idea that pairing them works better than either alone is a plausible hypothesis, not a demonstrated result.
What the Evidence Actually Shows
This is the part that matters most and the part the nickname tends to obscure. Neither BPC-157 nor TB-500 has been through large-scale peer-reviewed human clinical trials specific to how they're sold and used in the peptide research community. What exists is a body of preclinical and animal research on each compound, plus a large amount of community use and anecdotal reporting. That's a real evidence base, but it's a different kind of evidence base than a controlled human trial, and the "Wolverine" framing shouldn't be read as implying the second kind exists when what's actually there is the first.
For a closer look at what's actually been published on each compound, see the dedicated evidence reviews for BPC-157 and TB-500. Those pages go through the available research in more depth than is useful to repeat here.
Where to Find the Full Protocol
Looking for dosing and cycling details? This page is focused on explaining what the Wolverine stack is and where the name comes from. For injection dosing ranges, timing, and cycling schedules for BPC-157 and TB-500 together, see BioStackIQ's dedicated BPC-157 + TB-500 Stack protocol guide, which covers that ground in full.
Related Reading
For a comparison of BPC-157 against a different, shorter tissue-repair peptide, see BPC-157 vs KPV. Once a direction is chosen, BioStackIQ's Rate My Stack and Build Protocol can help plan and evaluate a stack before running it.